A number of studies have shown that bladder cancer cells harboring FGFR3 hyperactivating mutations and FGFR3-TACC3 fusion are responsive to FGFR3 inhibition [52,53,54,55]. The gene discussed is TACC3; the disease is urinary bladder carcinoma.